Bone hydroxyapatite and adjacent cellular DNA (HA/DNA)

Bone hydroxyapatite and adjacent cellular DNA represent a composite therapeutic target system primarily utilized by bone-seeking radiopharmaceuticals. Hydroxyapatite, the inorganic mineral component of the bone matrix, serves as the localization site for drugs that mimic calcium or possess high mineral affinity, such as Radium-223. Once these agents are incorporated into the bone at sites of active remodeling or metastatic growth, they emit ionizing radiation—specifically alpha or beta particles. This radiation travels a short distance to reach the DNA of adjacent cells, including metastatic cancer cells, osteoblasts, and osteoclasts. The resulting high-energy impact causes complex double-strand DNA breaks that are difficult for the cell to repair, leading to cell death. This dual-component target is critical for treating symptomatic bone metastases in cancers like castrate-resistant prostate cancer. By concentrating the cytotoxic effect within the bone microenvironment, this approach aims to limit systemic toxicity while addressing skeletal disease burden.

Other names

Bone mineral and genomic DNAHydroxyapatite matrixBone-seeking radiopharmaceutical target

Bone-seeking radiopharmaceuticals mimic calcium or utilize phosphonate ligands to integrate into the hydroxyapatite mineral at sites of high bone turnover. Once localized, the radioactive decay (alpha or beta emission) induces lethal double-strand DNA breaks in adjacent tumor cells and bone-remodeling cells.